The primary structure of BSP-30K, a major lipid-, gelatin-, and heparin-binding glycoprotein of bovine seminal plasma  by Calvete, Juan J. et al.
FEBS 17916 
The primary structure of BSP-30K, a major 
heparin-binding glycoprotein of bovine 
FEBS Letters 399 (1996) 147-152 
lipid-, gelatin-, and 
seminal plasma 
Juan J. Calveteal*, Karlheinz Mannb, Libia Sanz”, Manfred Raida”, Edda Tdpfer-Petersena 
aInstitut fiir Reproduktionsmedizin, Tieriirztliehe Hochschule Hannover, Biinteweg 15, 30559 Hannover-Kirchrode, Germany 
bMax-Planck-Institut fir Biochemie. Martinsried, Germany 
“Niedersiichsisches Institut ftir Peptid-Forschung GmbH, Hannover, Germany 
Received 8 October 1996; revised version received 30 October 1996 
Abstract BSP30K is a major acidic glycoprotein of bovine 
seminal plasma. It displays beparin-, gelatin-, and phospholipid- 
binding activities. BSP30K binds to spermatozoa upon ejacula- 
tion and is thought to play a role in sperm capacitation. We have 
determined its amino acid sequence, disulflde bonds, and 0- 
glycosylation sites. BSP30K consists of 158 amino acids 
arranged in a mosaic structure. BSP30K has a unique 4% 
residue N-terminal extension which includes three 7-8- amino 
acid repeats and the six O-glycosylated threonine residues. The 
polypeptlde stretch 49-71 is homologous to type ‘A’ domains 
found ln heparin-binding proteins from other mammalian species. 
The C-terminal portion of BSP30K is organized in a tandem of 
40-44-residue domains each sharing the consensus pattern of the 
gelatin-binding fibronectin type Il module. The mosaic structure 
of BSP30K suggests that this glycoprotein might be a factor 
contributing to the different sperm-capacitating effects exerted 
by heparin in different mammalian species. 
Key words: Protein BSP-30K; Heparin-binding protein; 
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1. Introduction 
Seminal plasma, a complex mixture of secretions originat- 
ing from the testis, epididymis, and accessory glands, serves as 
a vehicle for ejaculated spermatozoa, and contains factors that 
influence the fertilizing ability of sperm. In the bull, exposure 
of epididymal spermatozoa to seminal plasma enables sperm 
to be capacitated in vitro by heparin and to respond to ago- 
nists of the acrosome reaction [l]. Seminal plasma increases 
the number of binding sites for heparin on bovine epididymal 
sperm [2], and the regulatory role of seminal plasma heparin- 
binding proteins in capacitation of bovine spermatozoa by 
heparin has been documented [3,4]. 
Bovine seminal plasma contains four major acidic proteins, 
designated BSP-Al, BSP-A2, BSP-A3, and BSP-30K [3,5]. 
These proteins are secretory products of the seminal vesicles 
[5,6] and bind to spermatozoa upon ejaculation [7-lo]. The 
binding sites of the four BSP proteins on the sperm surface 
appear to be lipids: BSP-Al, BSP-A2, and BSP-A3 bind spe- 
cifically to phospholipids which contain the phosphorylcho- 
line (PC) group [ll]. BSP-30K, however, displays a much 
broader binding specificity. It preferentially binds to choline 
phospholipids but also interacts with phosphatidylethanol- 
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amine, phosphatidylserine, phosphatidylinositol, phosphatidic 
acid, and cardiolipin [ll]. The BSP proteins also bind to he- 
parin [3] and, when the purified proteins were coincubated 
with bovine epididymal sperm, all of them invoked synergis- 
tically and in a concentration-dependent manner in vitro 
sperm capacitation stimulated by heparin, as measured by 
the onset of acrosome reactions upon exposure to lysophos- 
phatidylcholine (LC) [12]. Bovine epididymal sperm undergo 
the LC-induced acrosome reaction only in the presence of 
BSP proteins and the BSP proteins cannot stimulate the acro- 
some reaction in the absence of heparin [12]. The mechanism 
by which these bovine seminal plasma proteins modulate 
sperm capacitation is unknown. It has been proposed that 
sperm-bound BSP proteins may interact with heparin-like gly- 
cosaminoglycans present in the female reproductive tract in 
particularly high concentration during the estrous cycle and 
thereby participate in the modifications of the plasma mem- 
brane that occur during capacitation [12,13]. Alternatively, or 
in addition, BSP proteins could act as intermediate molecules 
in a heparin-induced signal transduction pathway. 
The primary structures of BSP-Al, BSP-A2, and BSP-A3 
have been reported [14,15]. BSP-Al, also termed PDC-109 
[14] and Major Protein [6], has the same polypeptide chain 
as BSP-A2 but is O-glycosylated [10,16]. The structure of 
BSP-Al/A2 and BSP-A3 is made up of two homologous do- 
mains each displaying the consensus sequence of the fibronec- 
tin type II module. Here we report the amino acid sequence 
and posttranslational modifications of the other major BSP 
protein, BSP-30K. 
2. Methods 
2.1. Isolation of BSP-30K 
Ejaculate from healthy, reproductively active Holstein bulls was a 
generous gift of RPN (Rinder Produktion Niedersachsen, Verden, 
Germany). Spermatozoa were separated from seminal plasma by cen- 
trifugation at 1500 Xg for 15 min at room temperature. The super- 
natant was further clarified by centrifugation at 12 000 X g for 15 min. 
400 ml seminal plasma was applied to a heparin-Sepharose CL-6B 
(Pharmacia) column (3X 16 cm) equilibrated in 50 mM Tris-HCl, 
150 mM NaCl, 5 mM EDTA, 0.025% sodium azide, pH 7.4. The 
column was washed until the absorbance at 280 nm reached baseline, 
and BSP-30K was quantitatively recovered in a fraction eluted with 
column buffer containing 10 m&l o-phosphorylcholine (Sigma). This 
eluate was extensivelv dialvzed against 25 mM Tris-HCl, 1 M NaCl, 
pH 6.4, and applied ;o a DEAE-$ephadex A25 column (2.5 X 20 cm) 
equilibrated in the same buffer. BSP-30K, recovered in the flow- 
through eluate, was dialyzed against water, lyophilized, and purified 
by size-exclusion chromatography on a 16 X 60 cm HiLoad Superdex 
75 (Pharmacia) column equilibrated in 20 mM sodium phosphate, 150 
mM NaCl, 0.1% SDS, pH 7.4. Fractions containing apparently pure 
BSP-30K, as judged by SDS-polyacrylamide gel electrophoresis [17], 
were extensively dialyzed against MilliQ water and lyophilized. 
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GDIPDPGSKPXPSGMADELPXETYDLPPEIYZX 
~______________________________________ N-terminal sequencing _________________________________________ 
,_____________________ CB1 _______---__________, ,_____ T-lO/Ch-5 _________ 
, __________________________--- Tl,, _____________________----_________-----_____I 
, _____________ CB2 _____________________-_-----__-______---___ 
/__________________________-_________ D2 __ _ __ _ ___________--_________-_____ ( , _______________ D4 ___________ 
40 50 60 
ZFLPRXIYPQEEMPYDDKPFPSLLSKANDLNAV 
___________ , _________________________ CB3 __________________-__________ 
,________________ CB3/K1 ________________, 
I ,________ T12 _________ 
_________-______ JJ4 ____ ___ _____-___-___________, I---- T12/Ch-26a --- 
,_________ K2 __________ 
,_________ T*4 _________ 
70 80 90 
FEGPACAFPFTYKGKKYYMCTRKNSVLLWCSLD 
_______________ T12 ___________________________________--______________-______________-- 
_,,________ T12/Ch-19 _______, I-T12/Ch-7 -1 I-T12/Ch-5-j 
I---- T12/Ch-4 -----I ,_____________________--___-- CB4 ___________ 
______________________ K2 ________________,,__ K3__,,__-_----_____ K4 ______________ 
___________ T*4 __________________________, ,______ T12/Ch-12--e__, I- CB3/Ch-2 
,_____ T*l _______, ,_______________ T*4 ____________ 
100 110 120 130 
TEYQGNWKFCTERDEPECVFPFIYRKKSYESCT 
CB4 ____________________________________________________________~---__-____ 
,_______________ CB4/K3 ____________________________________I I  CB4,K4 ____ 
_--_____(,_T~2,Ch9_,,_________________ T12/Ch-22 ___________, I____ T5a _________ 
__________________________,,____ T*l __ ,,______________ T*3 __________________, /__ _____  T*2 ____. 
140 150 158 
RVHSFFWRRWCSLTSNYDRDKAWKYC ____________________------_____----------____------------______--------- 
__________________________----__-________-_______________-_-____________,,____ T5b _ _ I 
__, ,_______ 978 _ ______ _, I--- T12/Ch-3 ---((------- CB4/D4 ----I 
_- ,____________________ ','I2 ______________, , _T6 ______, 
(we_______ T*3 ________________, ______ T*2 ____, 
,______________________ w4 __________________, 
Fig. 1. The amino acid sequence of BSP-30K. CB, T, Ch, D, K, and W are peptides obtained by degradation of pyridylethylated BSP-30K 
with cyanogen bromide, trypsin, chymotrypsin, endoproteinase Asp-N, endoproteinase Lys-C, and CNBr/DMSO, respectively. T’ denotes tryp- 
tic peptides of native BSP-30K; X, unidentified residues, which correspond most probably to O-glycosylated threonines (see text). 
2.2. Enzymatic and chemical cleavages and isolation of 
peptides 
Native or reduced and pyridylethylated [18] BSP-30K was dissolved 
in 50 mM ammonium hydrogen carbonate, pH 8.3, 2 M guanidine 
hydrochloride to 2-5 mg/ml and was digested at 37°C overnight 
with trypsin (Sigma) and endoproteinases Lys-C and Asp-N (Boeh- 
ringer Mannheim) using a I:100 enzyme:substrate ratio. Peptides 
were isolated by reversed-phase HPLC on a Super Pat-Peps (Phar- 
macia) Cts column (0.4X25 cm, 5 urn particle size) eluting with a 
mixture of 0.1% TFA in water (solution A) and acetonitrile (solution 
B), first isocratically (lO%B) for 5 min, followed by 10_45%B for 175 
min, and 45-70%B for 10 min. Elution was monitored at 220 nm and 
peaks were collected manually. Peptides T-10 and T-12 were digested 
with a-chymotrypsin (1 :lOO enzyme:substrate ratio) in 0.2 M ammo- 
nium hydrogen carbonate, pH 8.3, for 6 h at 30°C. Chymotryptic 
fragments were separated either by reversed-phase HPLC using a 
Vydac Crs column (0.3 X 25 cm) eluting at a flow rate of 0.25 ml/ 
min with a gradient of 342%B for 160 min, or by size-exclusion 
chromatography using a Superdex Peptide column HR10/30 (Pharma- 
cia) equilibrated in 0.1% TFA and 25% acetonitrile and run at 0.3 ml/ 
min. 
Reduced and pyridylethylated BSP-30K (10 mg/ml in 70% formic 
acid) was degraded with cyanogen bromide (100 mg/ml final concen- 
tration) overnight at room temperature in Ns-flushed tubes in the 
dark. CNBr fragments were separated by reversed-phase HPLC on 
a Lichrospher (Merck) RP-100 Crs column (0.4 X 25 cm, 5 urn particle 
size) eluting at 1 mYmin, isocratically (lO%B) for 5 min, followed by 
10_50%B for 80 min, and 5&70%B for 20 min. Alternatively, CNBr 
fragments were separated by size-exclusion chromatography as above. 
Selected CNBr peptides were subfragmented with endoproteinase Lys- 
C (Wako Chemicals, Neuss, Germany; 1:50 enzyme:substrate ratio, 
in 0.1 M ammonium hydrogen carbonate, pH 8.3, containing 4 M 
urea, at 23°C for 16 h), a-chymotrypsin (Sigma) and endoproteinase 
Asp-N (as above). Peptides were isolated by reversed-phase HPLC as 
described above. 
Cleavage at tryptophan residues of reduced and pyridylethylated 
BSP-30K was performed with CNBr in dimethylsulfoxide (CNBrl 
DMSO) according to [19]. 
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2.3. Determination of thiol groups and disulfide bonds 
Titration of free cysteine residues and disulfide bonds was carried 
out as described [20]. For location of cystine residues, native BSP-30K 
was degraded with trypsin and the peptides were isolated by reversed- 
phase HPLC (as above) and characterized by amino acid analysis. 
2.4. Analytical methods 
Peptides were characterized by N-terminal sequence analysis (using 
Applied Biosystems sequencers 473A and Precise), amino acid com- 
position (using an Alpha Plus (Pharmacia) analyzer after sample hy- 
drolysis with 6 N HCl for 24 h at 1 10°C), and carbohydrate content. 
For amino sugar and neutral sugar analyses the samples were hydro- 
lyzed at 110°C with 4 N HCl for 4 h or 2 N HCl for 2 h, respectively. 
Sialic acid was determined after sample hydrolysis for 1 h at 80°C 
with 0.2 N TFA. Monosaccharides were resolved on a CarboPac PA1 
column (0.4X25 cm) eluting at 1 mUmin with either 16 mM NaOH 
(amino and neutral sugars) or 20 mM NaOH in 60 mM sodium 
acetate and analyzed using a Dionex DX-300 carbohydrate analyzer 
equipped with a pulsed amperometric detector and the AI-450 chro- 
matographic software [21]. 
The molecular mass of native BSP-30K was measured by electro- 
spray mass spectrometry using a Sciex API-III LC/MS/MS triple 
quadrupole instrument. 
2.5. Similarity search 
Amino acid sequence similarity searches were carried out using the 
program FASTA [22] implemented in the GCG Sequence Analysis 
Software Package and the protein sequences deposited in the data 
bank of the Martinsried Institute for Protein Sequences (MIPS). 
3. Results and discussion 
3.1. Isolation of BSPjOK, sequence determination, location of 
0-glycosylation sites and disulfide bonds 
The purification protocol described yielded 20-30 mg BSP- 
30K from 100 ml of bull seminal plasma. The protein was 
pure as judged by SDS-polyacrylamide gel electrophoresis, 
displayed a single peak by reversed-phase HPLC, and showed 
the N-terminal amino acid sequence GDIPDPGSKPXPSG- 
MADELPXETYDLPPEIYXXXFLPRXIYPQEEMPY. This 
sequence does not display discernible similarity with any 
known protein structure. 
The primary structure of BSP-30K was determined from 
overlapping peptides generated by enzymatic and chemical 
cleavage of the reduced and pyridylethylated protein (Fig. 
1). The residues at positions 11, 21, 32, 33, 34, and 39 could 
not be identified. However, carbohydrate analysis showed that 
BSP-30K contains 11 ? 1 mol galactosamine, 9 f 1 mol galac- 
tose, and 11 f 1 mol sialic acid per mol of protein. Our results 
are in agreement with the observation of Desnoyers et al. [23] 
that BSP-30K is the most glycosylated member of the BSP 
family containing neutral sugars, galactosamine, and sialic 
acid. Since glucosamine is not present in BSP-30K, we con- 
clude that the six unidentified residues may be 0-glycosylated. 
Moreover, amino acid analysis (Table 1) indicated that BSP- 
30K contains 6 threonine residues more than those calculated 
from its amino acid sequence (Fig. 1). This strongly suggests 
that all glycosylated residues of BSP-30K are threonines. 
Electrospray mass spectrometric analysis of native BSP- 
30K yielded broad clusters of protonated quasimolecular 
ions with 14, 15, and 16 positive charges, from which molec- 
ular masses in the range of 25 800-26400 Da were calculated. 
This indicates that BSP-30K may consist of a mixture of 
glycoforms. The isotope-averaged molecular mass of BSP- 
30K, calculated from the amino acid sequence shown in Fig. 
1 and assuming that the six unidentified residues are threo- 
nines, is 18 612 Da. Thus, glycosylation may account for 
7200-7800 Da, a value which is close to the 62467560 Da 
expected from the carbohydrate content of BSP-30K. 
BSP-30K contains 8 cysteine residues (Table 1). No thiol 
group was detected in native BSP-30K. Digestion with trypsin 
yielded 4 disulfide-linked peptides (labeled T* in Fig. 1) in a 
Cysi-Cys3, Cys’-Cys4, Cys5-Cys’, Cys’-Cyss arrangement 
(Fig. 3). 
3.2. Prediction of 0-glycosylation sites: the NetOGlyc server 
The BSP-30K sequence (assuming all X to be threonine 
residues) was submitted to the NetOGlyc server [24] for pre- 
diction of 0-glycosylation sites [25]. The only BSP-30K resi- 
dues which have a high probability of being 0-glycosylated 
(i.e. score > 0.5) are Thr” (0.665) and Thr3g (0.665). Threo- 
nines at positions 21, 23, 32, 33 have scores 0.495, 0.300, 
0.350, and 0.174, respectively. With the exception of Ser13, 
which has a score of 0.305, any other threonine and serine 
residue have values smaller than 0.17. These results support 
the claim that the NetOGlyc server may identify correctly 60- 
95% of the 0-glycosylated residues and 89-97% of the non- 
glycosylated residues in two independent test sets of unknown 
glycoproteins [24]. Although no consensus sequence for O- 
glycosylation has been recognized, 0-glycosylation sites are 
often found to cluster and to have a high abundance in the 
amino-terminal part of the protein [25]. As a whole, these data 
indicate the presence in bull seminal vesicles of N-acetylgalac- 
tosyltransferase activity acting at properly exposed BSP-30K 
threonine residues. 
3.3. BSP30K is a mosaic protein of the jibronectin type II 
domain-containing protein family 
An amino acid sequence similarity search identified BSP- 
30K as a novel member of the fibronectin type II (Fn-II) 
domain-containing protein family, which (among others) in- 
cludes the major heparin-binding proteins of bull and horse 
seminal plasma (reviewed in [26]). Thus, like bovine PDC-109 
Table 1 
Amino acid composition of pyridylethylated BSP-30K 
Residue mol% residues/molecule Sequence 
Asx 10.5 16.0 
Thr 8.6 13.1 
Ser 
Glx 
Pro 
Gly 
Ala 
PE-Cys 
Val 
Met 
Ile 
Leu 
Tyr 
Phe 
His 
Lys 
Arg 
Xaa 
(Tru) 
7.1 10.8 
8.7 13.2 
9.8 14.9 
4.4 6.7 
4.0 6.1 
5.3 8.1 
2.4 3.6 
1.7 2.6 
2.3 3.5 
6.2 9.4 
8.1 12.3 
6.6 10.0 
0.4 0.6 
8.0 12.2 
4.9 7.4 
16 
7 
11 
13 
16 
6 
6 
8 
4 
4 
10 
12 
10 
12 
8 
mol%, mol of residue per 100 mol of total amino acids: residues/ 
molecule, calculated from the amino acid analysis for a 153-residue 
BSP-30K (158 amino acids minus 5 tryptophan residues); Sequence, 
residues per molecule calculated from the amino acid sequence shown 
in Fig. 1. Amino acid residues are in the standard three-letter code. 
Asx, asparagine+aspartic acid; Glx, glutamine+glutamic acid; PE- 
Cys, pyridylethylated cysteine; Xaa, unidentified residue. 
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BSP-30K:lGDIPDPGSKPXPSGMADELPXETYDLPPEIYXXXFLPR 
I II III 
BSP-30K:39XIYPQEEMPYDDKPFPSLLSKANDLNAVFEGPA 
HSP-1 : 1DLOTTGADHSATVNP 
A 
BSP-30K: 72 CAFPFTYKG 
HSP-1 :16DOOLIM-------TK-HSATVTPE---NKCVFPFNYRG 
A’ 
PDC-109: ID Q D - - - EGVSTEPTQDGPA-ELPEDEE--CVFPFVYRN 
BSP-A3 :lDQQLSEDNVILPKEKKDPA-SGAETKDNKCVFPFIYGN 
c (2X) P F x Y (7X) 
BSP-30K:slKKYYMCTRKNSVLLWCSLDTEYQGNWK-FCTERDEPEC 
HSP-1 :43YRYYDCTRTDSFYRWCSLTGTYSGIQVRYCAATDYAKC 
PDC-109:33RKHFDCTVHGSLFPWCSLDADYVGRWK-YCAQRDYAKC 
BSP-A3 :38KKYFDCTLHGSLFLWCSLDADYTGRWK-YCTKNDYAKC 
c (8-10X) WC (4X) D Y (3-5X) W x Y C C 
+ + + + 
BSP-30K:llsVFPFIYRKKSYESCTRVHSFFWRR-WCSLTSNYDRDKA 
HSP-1 :75AFPFVYRGQTYDRCTTDGSLFRIS-WCSVTPNYDHHGA 
PDC-109:7oVFPFIYGGKKYETCTKIGSMWM-S-WCSLSPNYDKDRA 
BSP-A3 :75VFPFIYEGKSYDTCIKIGSTFM-NYWCSLSSNYDEDGV 
(2X) P F X Y (7X) C (8-10X) W C (4X) N Y (3-5X) 
+ + + + 
BSP-30K:lss W K Y C 
HSP-1 : 118 W K Y C 
PDC-109:106 W K Y C 
BSP-A3 : 111 W K Y C 
WXYC 
Fig. 2. Alignment of the amino acid sequence of BSP-30K with those of equine HSP-1 [28], and bovine PDC-109 [14] and BSP-A3 [15]. The 
occurrence of unique short repeats (designated I, II, and III) at the N-terminal part of BSP-30K, is indicated. A and A’ are homologous do- 
mains found in the equine and bovine proteins but absent in BSP30K. X denotes an unidentified residue (see Fig. 1); T, O-glycosylated threo- 
nine. The consensus amino acid residues of the fibronectin type II domain and the spacing between them [37] are shown below the sequence 
alignment. Residues essential for gelatin binding [27] are labelled with + below the sequence. 
and BSP-A3 and equine HSP-1, BSP-30K contains a tandem 
of Fn-II domains at the C-terminal part of the protein (Figs. 2 
and 3). Each of these repeats contains the conserved disulfide 
bridge pattern of the Fn-II domain, and most of the amino 
acid residues which have been identified by alanine scanning 
mutagenesis to be critical for gelatin binding of the fibronectin 
type II domain of human 92 kDa type IV collagenase [27]. In 
BSP-30K, the residue at position 99 is Glu instead of the 
consensus aspartic acid (Fig. 2). In HSP-1, which, like BSP- 
30K, binds gelatin [5,28], position 99 is threonine (Fig. 2), 
further indicating that this amino acid position does not 
need to be absolutely conserved for gelatin-binding activity. 
Comparison of the amino acid sequences of BSP-30K with 
those of PDC-109, BSP-A3, and HSP-1 shows that beside the 
conserved Fn-II modules, each of these proteins is built by 
mosaic structures displaying unique N-terminal extensions 
(Fig. 3). With the exception of BSP-A3 which is not glycosyl- 
ated [15], the N-terminal extensions of HSP-1 and PDC-109 
are, like that of BSP-30K, O-glycosylated at threonine resi- 
dues (Figs. 2 and 3). The single O-glycosylation site of PDC- 
109 is conserved in HSP-1 [28], but the other glycosylation 
sites of HSP-1 and BSP-30K are located in unique positions. 
In addition, BSP-30K contains, starting from the N-terminus, 
a proline-rich region (residues 1-16) and 3 short amino acid 
sequence repeats (stretches 17-24, 25-31, and 3541) (Fig. 2), 
which make BSP-30K unique among mammalian seminal 
plasma heparin-binding proteins (Fig. 3). 
3.4. Occurrence and biological role of proteins immunologically 
related to bovine BSP30K 
The biological role of the distinct mosaic architecture and 
glycosylation pattern of related proteins of different mammals 
is at present unclear. Moreover, the significance of several 
different BSP proteins having the same effect on sperm capac- 
itation mediated by heparin is not clear inasmuch as this effect 
appears to be synergistic and not additive [12]. We have pre- 
viously shown that glycosylation has an indirect effect on the 
ligand-binding activities of heparin-binding proteins from stal- 
lion [28,29] and boar seminal plasma [30] through modulation 
of their aggregation state. On the other hand, the biological 
effect of heparin on sperm physiology is not conserved among 
mammalian species. Thus, heparin plays a major role in in 
vitro capacitation of bull sperm [3,4], though in the horse 
this effect appears to be moderate [31], and no heparin is 
necessary for in vitro capacitation of porcine spermatozoa. 
Interestingly, the major seminal plasma heparin-binding 
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I II III 
1~ BSP-JOK ~1 
1 16 29 75 121 
::.::... 
:fii;iyi B 
:,.:.:,,.: B’ 
AULI 
S-S 
S-S] 
S-S 
s-s - 
? HSP-1 1 
1 19 
m] 
+ PDC-109 ____( 
t------- BSP-A3 - 
Fig. 3. Scheme of the arrangement of domains in the structures of 
BSP-30K, HSP-1, PDC-109, and BSP-A3; ??, relative position of 
O-glycosylation sites. S-S, disulfide bridge. I, II, and III represent 
short amino acid sequence repeats uniquely found in BSP-30K; A, 
A’ are homologous domains found at the N-terminal part of HSP-1 
(both domains) and PDC-109 and BSP-A3 (only domain A’); the 
polypeptide stretches 1-16 and 41-71 of BSP-30K are sequences 
without similarity to any known protein. 
(Hep+) proteins in these three species belong to only two 
different protein families: in the bull, BSP proteins account 
for over 95% of Hep+. In the pig, however, 90% of all Hep+ 
belong to the spermadhesin protein family [32,33]. The horse 
represents an intermediate situation containing a large pro- 
portion (70%) of HSP-1 and HSP-2 (of the BSP protein fam- 
ily) [26,34] but also a substantial amount of HSP-7 (15%), a 
member of the spermadhesin protein family [34,35]. 
Using specific antibodies, Leblond et al. [36] have shown 
that phosphorylcholine-binding proteins from the seminal 
fluids of different mammalian species share antigenic determi- 
nants with the major proteins of bovine seminal plasma BSP- 
AllA2, BSP-A3, and BSP-30K. In the pig, proteins with ap- 
parent molecular masses of 14, 64, and 70 kDa were recog- 
nized by the anti-BSP-30K antibody. Human seminal plasma 
showed 58 and 67 kDa BSP-30K-related polypeptides, and 70 
kDa proteins were immunodetected in hamster and rat. Thus, 
proteins immunochemically related to BSP-30K in different 
mammals may have distinct structural features. 
From the above considerations, it seems plausible to pro- 
pose that the modulatory effect on sperm capacitation exerted 
by heparin might be due to a combination of the chemical 
structure and aggregation state of the heparin-binding pro- 
teins, and their relative abundance and topography on the 
sperm surface. The unique modular structure of BSP-30K 
suggests that this glycoprotein may be one of the factors con- 
151 
tributing to the specific bovine spermatozoon phenotype, 
which in turn may modulate species-specific effects of heparin 
on sperm capacitation. 
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